恒瑞医药：关于获得美国FDA孤儿药资格认定的公告

Core Viewpoint - Heng Rui Medicine has received orphan drug designation from the U.S. FDA for its product, injection of Rukang Qutuzumab combined with Adebali injection and chemotherapy for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma [1] Group 1 - The orphan drug designation is aimed at drugs used for the prevention, treatment, or diagnosis of rare diseases [1] - This designation will provide the company with opportunities for policy support in product development, registration, and commercialization in the U.S. [1]